Mira Pharmaceuticals reported revenue growth of 465.91% and asset growth of 279.52% for the quarter ended Dec 2025. These growth metrics cover 14 quarters of results from Sep 2022 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Growth MetricsGrowth | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth Ratios | ||||||||||||||
| Assets Growth (1y) | 474.83% | -52.69% | -40.74% | -63.23% | 78.91% | 279.52% | ||||||||
| Assets Growth (3y) | 134.70% | |||||||||||||
| Assets (QoQ) | 135.76% | -45.31% | -22.78% | -31.49% | -52.09% | -37.99% | 779.09% | 45.33% | ||||||
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | -96.99% | 3,031.20% | 1,211.35% | 261,478.58% | -29.37% | -38.45% | -65.81% | -36.26% | 124.04% | |||||
| Cash & Equivalents Growth (3y)Cash & Equiv. Growth (3y) | -4.01% | 141.56% | 162.48% | |||||||||||
| Cash & Equivalents (QoQ)Cash & Equiv. (QoQ) | -77.31% | 87.27% | -99.62% | 1,740.10% | 23,540.70% | -21.57% | -23.33% | -31.65% | -57.42% | -39.44% | 261.62% | 140.27% | ||
| Cash from Operations Growth (1y)Cash from Ops. Growth (1y) | -33.94% | -6.11% | 2.40% | -30.74% | -4.59% | -74.40% | -55.31% | 7.44% | 40.45% | 34.99% | ||||
| Cash from Operations Growth (3y)Cash from Ops. Growth (3y) | 5.86% | -6.35% | ||||||||||||
| Cash from Operations (QoQ)Cash from Ops. (QoQ) | 25.82% | -10.24% | 38.55% | -166.53% | 41.23% | -1.40% | 17.68% | -113.22% | 2.01% | 9.70% | 50.94% | -37.18% | -6.97% | |
| EPS (Basic) Growth (1y) | 48.61% | -91.31% | -305.77% | -15.37% | -20.32% | 48.45% | 50.15% | -22.95% | 20.89% | -768.25% | -62.52% | |||
| EPS (Basic) Growth (3y) | 21.21% | -104.59% | -48.69% | |||||||||||
| EPS (Basic) (QoQ) | 25.70% | 44.13% | 1.66% | -25.88% | -176.60% | -18.50% | 72.04% | -31.28% | -18.51% | -14.58% | 31.03% | 15.53% | -1,200.64% | 78.55% |
| EPS (Diluted) Growth (1y) | 48.61% | -91.31% | -305.77% | -15.37% | -20.32% | 48.45% | 50.15% | -22.95% | 20.89% | -768.25% | -99.78% | |||
| EPS (Diluted) Growth (3y) | 21.21% | -104.59% | -59.28% | |||||||||||
| EPS (Diluted) (QoQ) | 25.70% | 44.13% | 1.66% | -25.88% | -176.60% | -18.50% | 72.04% | -31.28% | -18.51% | -14.58% | 31.03% | 15.53% | -1,200.64% | 73.64% |
| FCF Margin Growth (1y) | 0.40M | 0.42M | ||||||||||||
| FCF Margin (QoQ) | 0.01M | 0.84M | 0.03M | |||||||||||
| Free Cash Flow Growth (1y)FCF Growth (1y) | -33.94% | -6.11% | 2.40% | -30.74% | -4.59% | -74.40% | -55.31% | 7.44% | 40.45% | 34.99% | ||||
| Free Cash Flow Growth (3y)FCF Growth (3y) | 5.86% | -6.35% | ||||||||||||
| Free Cash Flow (QoQ)FCF (QoQ) | 25.82% | -10.24% | 38.55% | -166.53% | 41.23% | -1.40% | 17.68% | -113.22% | 2.01% | 9.70% | 50.94% | -37.18% | -6.97% | |
| Net Cash Flow Growth (1y)NCF Growth (1y) | 1,015.10% | -873.87% | -207.15% | -3,102.96% | -77.40% | -3.62% | -51.47% | 32.50% | 44.69% | 379.58% | ||||
| Net Cash Flow Growth (3y)NCF Growth (3y) | 70.91% | 181.98% | ||||||||||||
| Net Cash Flow (QoQ)NCF (QoQ) | 125.61% | -313.76% | 106.71% | 24,793.53% | -121.66% | 15.16% | 34.36% | 287.37% | -199.31% | -24.02% | 70.75% | 501.64% | 91.89% | |
| Net Income Growth (1y) | 47.75% | -98.15% | -328.86% | -28.09% | -33.58% | 43.03% | 58.54% | -3.84% | 9.08% | 44.34% | -147.63% | |||
| Net Income Growth (3y) | 14.06% | 14.35% | -63.91% | |||||||||||
| Net Income (QoQ) | 25.27% | 25.47% | 0.63% | 5.59% | -183.37% | -61.31% | 70.32% | 1.54% | -20.84% | -17.41% | 25.67% | 13.79% | 26.02% | -422.34% |
| Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) | 47.75% | -98.15% | -328.86% | -28.09% | -33.58% | 43.03% | 58.54% | -3.84% | 9.08% | -1,010.37% | -149.34% | |||
| Net Income towards Common Stockholders Growth (3y)Net Income Growth (3y) | 14.06% | -132.29% | -64.28% | |||||||||||
| Net Income towards Common Stockholders (QoQ)Net Income (QoQ) | 25.27% | 25.47% | 0.63% | 5.59% | -183.37% | -61.31% | 70.32% | 1.54% | -20.84% | -17.41% | 25.67% | 13.79% | -1,375.86% | 73.64% |
| Net Margin Growth (1y) | -1.26M | 0.35M | ||||||||||||
| Net Margin (QoQ) | -0.09M | -0.02M | 1.53M | |||||||||||
| Revenue Growth (1y) | 232.95% | 465.91% | ||||||||||||
| Revenue (QoQ) | 0.94% | 1,357.69% | 71.56% | |||||||||||
| Share-based Compensation Growth (1y)Stock Comp. Growth (1y) | 882.50% | 44.66% | 238.44% | -17.96% | -81.47% | 155.73% | 74.89% | -13.16% | 48.69% | 725.41% | ||||
| Share-based Compensation Growth (3y)Stock Comp. Growth (3y) | 39.36% | 212.56% | ||||||||||||
| Share-based Compensation (QoQ)Stock Comp. (QoQ) | 0.00% | 0.00% | 398.78% | 96.98% | -85.28% | 133.95% | 20.91% | -55.52% | 103.26% | 59.99% | -39.97% | -23.84% | 1,028.29% |
Pull Mira Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=MIRA&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "MIRA", "statement": "Growth", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=MIRA&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();